According to the results of a systematic review & meta-analysis, evidence supporting the clinical benefit of niacin monotherapy for secondary prevention of Cardiovascular Disease appears to be outdated and require various innovative trials to determine its role in CVD management.
Scientists performed a systematic review and meta-analysis to identify clinical trials assessing the effect of niacin on lipid modification and CVD risk To determine the role of niacin in CVD prevention.
The results from the study shows that while there is evidence to support the clinical benefit of niacin in the prevention of CVD, this evidence was obtained from older trials with study populations that most likely have differing baseline characteristics (i.e., underlying cardiovascular risk) compared to patient populations seen today. The authors concluded that “Niacin may have a role as a monotherapy drug for lipid control in statin-intolerant patients, but, given substantial advancements in cardiovascular disease management since 1990, this indication should be restudied in current-day patients receiving usual baseline care.”
No comments:
Post a Comment
Note: only a member of this blog may post a comment.